Cargando…

Comparison of Patient Survival According to Erythropoiesis-Stimulating Agent Type of Treatment in Maintenance Hemodialysis Patients

This study aimed to evaluate the difference in patient survival according to the type of erythropoiesis-stimulating agent (ESA) treatment used in the Korean hemodialysis (HD) population. This retrospective study analyzed the laboratory data from a national HD quality assessment program and the claim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kang, Seok Hui, Kim, Bo Yeon, Son, Eun Jung, Kim, Gui Ok, Do, Jun Young
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861937/ https://www.ncbi.nlm.nih.gov/pubmed/36675553 http://dx.doi.org/10.3390/jcm12020625

Ejemplares similares

Effects of Proton Pump Inhibitors on Patient Survival in Patients Undergoing Maintenance Hemodialysis
por: Kang, Seok Hui, et al.
Publicado: (2023)

Association of Renin-Angiotensin System Blockers with Survival in Patients on Maintenance Hemodialysis
por: Kang, Seok Hui, et al.
Publicado: (2023)

Comparison between the Effects of Allopurinol and Febuxostat on the Survival of Patients on Maintenance Hemodialysis
por: Kang, Seok Hui, et al.
Publicado: (2023)

Roxadustat treatment for erythropoiesis-stimulating agent-hyporesponsive anemia in maintenance hemodialysis patients
por: Song, Jie, et al.
Publicado: (2023)

Resistance to Erythropoiesis-Stimulating Agents Is Associated with Arterial Microcalcification in Early Hemodialysis Patients
por: Won, Hye Sung, et al.
Publicado: (2014)

Association between Iron Status and Survival in Patients on Chronic Hemodialysis
por: Kang, Seok-Hui, et al.
Publicado: (2023)

Use of erythropoiesis-stimulating agents in obese hemodialysis patients
por: Park, Sun-Hee
Publicado: (2018)

Selenium Associates With Response to Erythropoiesis-Stimulating Agents in Hemodialysis Patients
por: Yasukawa, Minoru, et al.
Publicado: (2022)

Parathyroidectomy Improves the Consumption of Erythropoiesis-Stimulating Agents in Hemodialysis Patients
por: Lee, Yu-Ting, et al.
Publicado: (2022)

Association of plasma F2-isoprostanes and isofurans concentrations with erythropoiesis-stimulating agent resistance in maintenance hemodialysis patients
por: Rivara, Matthew B., et al.
Publicado: (2015)

Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients
por: Suttorp, Marit M, et al.
Publicado: (2013)

Association of the erythropoiesis-stimulating agent resistance index and the geriatric nutritional risk index with cardiovascular mortality in maintenance hemodialysis patients
por: Yajima, Takahiro, et al.
Publicado: (2021)

Influence of Different Types of β-Blockers on Mortality in Patients on Hemodialysis
por: Kang, Seok-Hui, et al.
Publicado: (2023)

Correlation between Statin Solubility and Mortality in Patients on Chronic Hemodialysis
por: Kang, Seok-Hui, et al.
Publicado: (2023)

Regulation of platelet count by erythropoiesis-stimulating agents – iron axis in hemodialysis patients
por: Koike, Kiyomi, et al.
Publicado: (2016)

Regular laboratory testing and patient survival among patients undergoing maintenance hemodialysis: a Korean nationwide cohort study
por: Kim, Do Hyoung, et al.
Publicado: (2023)

Associations among Erythroferrone and Biomarkers of Erythropoiesis and Iron Metabolism, and Treatment with Long-Term Erythropoiesis-Stimulating Agents in Patients on Hemodialysis
por: Honda, Hirokazu, et al.
Publicado: (2016)

Implications of a Reduction in the Hemoglobin Target in Erythropoiesis-Stimulating Agent-Treated Hemodialysis Patients
por: Nguyen, Timothy V., et al.
Publicado: (2011)

The effect of altitude on erythropoiesis-stimulating agent dose, hemoglobin level, and mortality in hemodialysis patients
por: Sibbel, Scott, et al.
Publicado: (2016)

Responsiveness to an erythropoiesis-stimulating agent is correlated with body composition in patients undergoing chronic hemodialysis
por: Lee, Hyang Yun, et al.
Publicado: (2022)

Medium cut-off dialyzer improves erythropoiesis stimulating agent resistance in a hepcidin-independent manner in maintenance hemodialysis patients: results from a randomized controlled trial
por: Lim, Jeong-Hoon, et al.
Publicado: (2020)

Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents
por: Haase, Volker H, et al.
Publicado: (2019)

Serum trace metal association with response to erythropoiesis stimulating agents in incident and prevalent hemodialysis patients
por: Brier, Michael E., et al.
Publicado: (2020)

Erythropoiesis stimulating agents are associated with serum fibroblast growth factor 23 metabolism in patients on hemodialysis
por: Honda, Hirokazu, et al.
Publicado: (2020)

Hepcidin-25 in Chronic Hemodialysis Patients Is Related to Residual Kidney Function and Not to Treatment with Erythropoiesis Stimulating Agents
por: van der Weerd, Neelke C., et al.
Publicado: (2012)

The Resection of Thyroid Cancer Was Associated with the Resolution of Hyporesponsiveness to an Erythropoiesis-stimulating Agent in a Hemodialysis Patient with Aceruloplasminemia
por: Nagata, Soichiro, et al.
Publicado: (2017)

Roxadustat alleviates the inflammatory status in patients receiving maintenance hemodialysis with erythropoiesis-stimulating agent resistance by increasing the short-chain fatty acids producing gut bacteria
por: Zhao, Xiu-Nan, et al.
Publicado: (2023)

Erythropoiesis-Stimulating Agent Treatment in Patients With COVID-19
por: Fishbane, Steven, et al.
Publicado: (2020)

The Korean Clinical Research Center for End-Stage Renal Disease Study Validates the Association of Hemoglobin and Erythropoiesis-Stimulating Agent Dose with Mortality in Hemodialysis Patients
por: Kwon, Owen, et al.
Publicado: (2015)

Comparison between short- and long-acting erythropoiesis-stimulating agents in hemodialysis patients: target hemoglobin, variability, and outcome
por: Bernieh, Bassam, et al.
Publicado: (2014)

Low versus high dose erythropoiesis-stimulating agents in hemodialysis patients with anemia: A randomized clinical trial
por: Saglimbene, Valeria, et al.
Publicado: (2017)

Synergistic deterioration of prognosis associated with decreased grip strength and hyporesponse to erythropoiesis-stimulating agents in patients undergoing hemodialysis
por: Kobayashi, Shizuka, et al.
Publicado: (2022)

Investigating the relationship between erythropoiesis-stimulating agents and mortality in hemodialysis patients: A systematic review and meta-analysis
por: Karimi, Zahra, et al.
Publicado: (2023)

Erythropoiesis-stimulating Agents and Anemia in Patients with Non-dialytic Chronic Kidney Disease
por: Kim, Sun Moon, et al.
Publicado: (2016)

Treatment of renal anemia: Erythropoiesis stimulating agents and beyond
por: Biggar, Patrick, et al.
Publicado: (2017)

Pharmacovigilance in practice: erythropoiesis-stimulating agents
por: Hedenus, Michael, et al.
Publicado: (2014)

Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients
por: Gupta, Ajay, et al.
Publicado: (2015)

Association between initial vascular access and survival in hemodialysis according to age
por: Kim, Ha Yeon, et al.
Publicado: (2019)

Erythropoiesis stimulating agents: approaches to modulate activity
por: Sinclair, Angus M
Publicado: (2013)

Altitude Pre-Acclimatization with an Erythropoiesis-Stimulating Agent
por: Heldeweg, Micah L. A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cjstaddo0dmovgo4jlghai1l5i